The short version of triagonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-29 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
The Jalisco New Generation Cartel (CJNG) (Spanish: Cártel de Jalisco Nueva Generación) is a Mexican criminal group based in Jalisco and was headed by Nemesio Oseguera Cervantes ("El Mencho"), who was Mexico's most-wanted cartel leader until his death in 2026. The CJNG started as one of the splits of Milenio Cartel, beside La Resistencia. The CJNG defeated La Resistencia and took control of Millenio Cartel's smuggling networks. The cartel expanded its operation network from coast to coast in only six months, making it one of the criminal groups with the greatest operating capacity in Mexico as of 2012. Through online messaging, the Jalisco New Generation Cartel has tried to seek social approval and tacit consent from the Mexican government to confront Los Zetas by posing as a "righteous" and "nationalist" group. By 2018 the CJNG was claimed to be the most powerful cartel in Mexico, though Insight Crime has said the Sinaloa Cartel is still the most powerful cartel and the CJNG its closest rival. In 2019, the group was weakened by infighting, arrests of senior operatives, and a war with the Sinaloa Cartel and its allies.
During the fall of 1924, Marvel found him a job as an assistant biochemist at the Philadelphia General Hospital that helped him to teach clinical chemistry at the Graduate School of Medicine, University of Pennsylvania. Marvel would pay for the trip to Pennsylvania in exchange for du Vigneaud's preparation of 10 pounds of cupferron. Resuming his academic career in 1925, du Vigneaud joined the group of John R. Murlin at the University of Rochester for his PhD thesis. He graduated in 1927 with his work The Sulfur of Insulin. After a post-doctoral position with John Jacob Abel at Johns Hopkins University Medical School (1927–1928), he traveled to Europe as a National Research Council Fellow in 1928–1929, where he worked with Max Bergmann and Leonidas Zervas at the Kaiser Wilhelm Institute for Leather Research in Dresden, and with George Barger at the University of Edinburgh Medical School. He then returned to the University of Illinois as a professor. In 1932, he started working at the George Washington University Medical School in Washington, D.C., and in 1938, he attended the Cornell Medical College in New York City, where he stayed until his emeritation in 1967. Following retirement, he held a position at Cornell University in Ithaca, New York. In 1974, du Vigneaud had a stroke which forced his retirement. He died in 1978, one year after his wife's death in 1977.
=== In media === In the Stephen King short story collection Night Shift, the final story of the book, "The Woman in the Room", tells a tale in which the main character contemplates and then finally performs a mercy killing using a drug called "Darvon Complex". In his 1976 song "My Head Hurts My Feet Stink and I Don't Love Jesus" Jimmy Buffett references taking a Darvon to relieve his hangover.
=== Side effects === Adverse side effects are common and often require dose reduction or outright discontinuation. Common side effects include fatigue, headache, insomnia, depression, mood swings, hair loss, nausea, diarrhea, myalgia and associated skeletal pain, anorexia, fever etc. Relatively rare effects include imbalance of thyroid hormones, xerostomia, thrombocytopenia, hepatomegaly, pharyngitis, cough, psychosis, rashes, arrhythmia, anemia etc. Severe side effects may include a range of potentially fatal neuropsychiatric, autoimmune, ischemic, or infectious disorders.
Sources: en.wikipedia.org
Kimon Georgiev Stoyanov (Bulgarian: Кимон Георгиев Стоянов; August 11, 1882 – September 28, 1969) was a Bulgarian general who was the Prime Minister of the Kingdom of Bulgaria from 1934 to 1935 and again from 1944 to 1946. He was considered a "master in the art of coup d'états".
van Heyningen, professor emeritus, University of Oxford, UK, and John R. Seal, former scientific director, National Institute of Allergy and Infectious Diseases, Bethesda, note that De's paper "deserves to go down as a classic in the history of cholera, and, indeed, as later developments have shown, in the history of cellular physiology and biochemistry." Thanks to De's discovery of the cholera enterotoxin, research has been redirected to find a vaccine that will spark the immune system to fight the enterotoxin specifically, rather than the bacteria. De and colleagues also published highly cited pioneering studies on V. cholerae action on the intestinal membrane.,, The 1953 paper “An experimental study of the mechanism of action of Vibrio cholerae on the intestinal mucous membrane” is De’s most-cited paper, cited 340 times until August 1986. It was especially influential on research fronts on "E. coli and Vibrio cholerae enterotoxin: detection, characterization, and role of adherence" and "Characterization of cholera enterotoxin and other enterotoxins". John Craig of State University of New York Health Science Center at Brooklyn described De’s work as truly creative and novel, having “forever altered our concepts surrounding the pathogenesis of secretory diarrhoea.” These findings resulted from work he conducted at the Nilratan Sircar Medical College, Calcutta Medical College, and Bose Institute in Kolkata. His research used relatively simple and inexpensive methods. In the words of Nobel Laureate Prof.
An association between hearing loss and high level exposures to PFNA was also reported in 2020. PFOA is classified as carcinogenic to humans (Group 1) by the International Agency for Research on Cancer (IARC), with significant associations with the onset of liver, pancreatic, and uterine cancers. IARC also classified PFOS as possibly carcinogenic to humans (Group 2b) based on "strong" mechanistic evidence. Evidence suggests PFOA, perfluorohexanesulfonic acid (PFHxS), and perfluorononanoic acid (PFNA) cause hepatotoxicity in humans and links PFAS exposure to male infertility.
=== Aliases === As with many other genes, there are some common aliases found with this gene. Those aliases are Lymphocyte-Activation Gene-1 (LAG1) Interacting Protein, Transparent Testa Glabra 1 (TTG1), and Odorant Response Abnormal 4 (ODR4). The most common alias for C1orf27 is ODR4, and this is what most readily appears when searching the gene.
Human Vapor (Japanese: ガス人間; Korean: 가스인간) is a 2026 science fiction crime thriller television series based on the 1960 tokusatsu film The Human Vapor by Ishirō Honda and Takeshi Kimura. A Japanese–South Korean co-production written by Yeon Sang-ho and Ryu Yong-jae and directed by Shinzo Katayama, the series stars Shun Oguri, Yu Aoi, Suzu Hirose, Kento Hayashi, Uta, and Yutaka Takenouchi. It is produced by Toho Studios and Wow Point, marking the first collaboration between Netflix and Toho, and was released on Netflix on July 2, 2026.
Sources: en.wikipedia.org
== History == Food technologists have long known that protein hydrolysis produces a meat bouillon-like odor and taste. Hydrolysates have been a part of the human diet for centuries, notably in the form of fermented soy sauce, or Shoyu. Shoyu, traditionally made from wheat and soy protein, has been produced in Japan for over 1,500 years, following its introduction from mainland China. The origins of producing these materials through the acid hydrolysis of protein (aHVP) can be traced back to the scarcity and economic challenges of obtaining meat extracts during the Napoleonic wars. In 1831, Berzelius obtained products having a meat bouillon taste when hydrolysing proteins with hydrochloric acid. Julius Maggi produced acid-catalyzed hydrolyzed vegetable protein industrially for the first time in 1886. In 1906, Fischer found that amino acids contributed to the specific taste. In 1954, D. Phillips found that the bouillon odor required the presence of proteins containing threonine. Another important substance that gives a characteristic taste is glutamic acid.
The results are supported by the simulations which show that at approximately 12 mol% of ethanol the membrane was no longer able to tolerate and adapt to the presence of the ethanol resulting in non-lamellar phases. The formations of the non-lamellar phases are described as being irreversible inverted-micelles. This irreversibility of the inverted-micelles are supported by mass density profiles which display an overlapping of leaflets from opposite membranes that interact forming a strong interlocking between the acyl chains or hydrophobic region with and without the presence of ethanol. Snapshots of the simulations are produced at 100 ns which compared the phospholipid membrane system in the presence of ethanol and in the absence of ethanol which continues to support ethanol's preference to bind near the hydrophilic region of the phospholipid. The researchers also added monovalent ions as salt ions (NaCl) to the phospholipid membrane system which formed non-lamellar phases (micelles) as well. This phenomenon is important because they predict that in the presence of ethanol the micelles can serve as transporters for hydrophilic structures across the membrane. Overall, in this study it shows that ethanol is able to penetrate throughout the membrane. I very important point that was revealed in this study is the fact that ethanol can destroy epithelial tissues (lips, throat, stomach, mouth) in humans. Therefore, one must consider some of the damaging effects of some alcoholic beverages that can contain up to 40% of ethanol (v/v).
To identify the sodium-channel binding surface of d-ACTX-Ar1a, scientist must synthesize analogues with selected residue changes. Studies will contribute to a more detailed mapping of site-3, the neurotoxin receptor site on the sodium-channel and provide structure-activity data critical for determining the phyla-specific actions of this and related atracotoxins.
More than 20 nations, most notably the United Kingdom, joined the United States in invading Iraq as part of the "coalition of the willing". They launched the invasion on March 20, 2003. The Iraqi military was quickly defeated. The capital, Baghdad, fell on April 9, 2003. On May 1, Bush declared the end of major combat operations in Iraq. The initial success of U.S. operations increased his popularity, but the U.S. and allied forces faced a growing insurgency led by sectarian groups; Bush's "Mission Accomplished" speech was later criticized as premature. From 2004 until 2007, the situation in Iraq deteriorated further, with some observers arguing that there was a full-scale civil war in Iraq. Bush's policies met with criticism, including demands domestically to set a timetable to withdraw troops from Iraq. The 2006 report of the bipartisan Iraq Study Group, led by James Baker, concluded that the situation in Iraq was "grave and deteriorating". While Bush admitted there were strategic mistakes made in regard to the stability of Iraq, he maintained he would not change the overall Iraq strategy. According to Iraq Body Count, some 251,000 Iraqis have been killed in the civil war following the U.S.-led invasion, including at least 163,841 civilians. In January 2005, elections recognized by the West as free and fair were held in Iraq for the first time in 50 years. This led to the election of Jalal Talabani as president and Nouri al-Maliki as Prime Minister of Iraq. A referendum to approve a constitution in Iraq was held in October 2005, supported by most Shiites and many Kurds.
The American Medical Association (AMA) believes that a physician's opinion on capital punishment is a personal decision. Since the AMA is founded on preserving life, they argue that a doctor "should not be a participant" in executions in any professional capacity with the exception of "certifying death, provided that the condemned has been declared dead by another person" and "relieving the acute suffering of a condemned person while awaiting execution." The AMA, however, does not have the ability to enforce its prohibition of doctors' participation in lethal injection. Medical licensing is handled at the state level; it does not have the authority to revoke medical licenses. Typically, most states do not require that physicians administer the drugs for lethal injection, but most states do require doctors, nurses or paramedics to prepare the substances before their application and to attest to the inmate's death after it. Some states specifically detail that participation in a lethal injection is not to be considered practicing medicine. For example, Delaware law reads, "the administration of the required lethal substance or substances required by this section shall not be construed to be the practice of medicine, and any pharmacist or pharmaceutical supplier is authorized to dispense drugs to the Commissioner or the Commissioner's designee, without prescription, for carrying out the provisions of this section, notwithstanding any other provision of law" (excerpt from Title 11, Chapter 42, § 4209).
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.